Pfizer and Sanofi-Aventis Statement on Status of Exubera
Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said that the U.S. food and Drug Administration has notified the companies that it is extending its original review period for Exubera® (insulin [rDNA origin] powder for oral inhalation) by three months to review additional technical chemistry data submitted by the companies.
In September, an FDA Advisory Committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. FDA is not obligated to follow the Advisory Committee's recommendation, but usually does so. Pfizer and sanofi-aventis continue to work closely with the FDA so that this important medicine can be made available for patients.
Most read news
Other news from the department research and development

Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.